Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Public ClinicalTrials.gov record NCT00833248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.
Study identification
- NCT ID
- NCT00833248
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 246 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2009 (Type not available)
- Primary completion
- Sep 2011 (Actual)
- Completion
- Sep 2011 (Actual)
- Last update posted
- Oct 4, 2012
2009 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Research Center | Birmingham | Alabama | 35209 | — |
| Urology Centers of Alabama | Homewood | Alabama | 35209 | — |
| Alaska Urological Association | Anchorage | Alaska | 99508 | — |
| Arizona Urologic Specialists | Tuscon | Arizona | 85712 | — |
| Orange County Urology | Lagua Hills | California | 92653 | — |
| Tri-Valley Urology Medical Group | Murrieta | California | 92563 | — |
| Connecticut Clinical Research Center | Middlebury | Connecticut | 06762 | — |
| South Florida Medical Research | Aventura | Florida | 33180 | — |
| DCT -Celebration, LLC dba Discovery Clinical Trials | Celebration | Florida | 34747 | — |
| Pinellas Urology Inc. | St. Petersburg | Florida | 33710 | — |
| Palm Beach Urology Associates | Wellington | Florida | 33449 | — |
| Summit Research Institute | Bloomington | Indiana | 47403 | — |
| Northeast Indiana Research | Fort Wayne | Indiana | 46825 | — |
| Urology Center Research Institute | Englewood | New Jersey | 07631 | — |
| Urology Group of New Mexico | Albuquerque | New Mexico | 87109 | — |
| Premier Medical Group of Hudson | Baldwinsville | New York | 12601 | — |
| University Urology Associates | New York | New York | 10016 | — |
| Urology Associates | Nashville | Tennessee | 37209 | — |
| Urology of Virginia | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00833248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 4, 2012 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00833248 live on ClinicalTrials.gov.